Zacks Research Has Pessimistic Outlook of ALLO Q2 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Stock analysts at Zacks Research reduced their Q2 2025 earnings estimates for Allogene Therapeutics in a research report issued on Thursday, January 9th. Zacks Research analyst R. Department now forecasts that the company will post earnings of ($0.38) per share for the quarter, down from their prior estimate of ($0.37). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.27) per share. Zacks Research also issued estimates for Allogene Therapeutics' Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.57) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.75) EPS.

Several other analysts have also issued reports on ALLO. HC Wainwright reiterated a "buy" rating and set a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. Piper Sandler decreased their price target on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Finally, William Blair reissued an "outperform" rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $9.73.

Allogene Therapeutics Stock Down 4.9 %

Shares of NASDAQ:ALLO traded down $0.10 during trading on Monday, reaching $1.96. 630,481 shares of the company traded hands, compared to its average volume of 2,764,959. The firm has a fifty day simple moving average of $2.32 and a 200 day simple moving average of $2.54. Allogene Therapeutics has a 1-year low of $1.78 and a 1-year high of $5.78. The firm has a market cap of $410.96 million, a P/E ratio of -1.26 and a beta of 0.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in Allogene Therapeutics during the 2nd quarter valued at about $6,349,000. Lynx1 Capital Management LP bought a new position in shares of Allogene Therapeutics in the second quarter valued at approximately $5,192,000. Renaissance Technologies LLC boosted its holdings in shares of Allogene Therapeutics by 340.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company's stock worth $4,073,000 after acquiring an additional 1,351,055 shares in the last quarter. Zacks Investment Management acquired a new stake in Allogene Therapeutics during the 3rd quarter valued at $1,446,000. Finally, Dimensional Fund Advisors LP boosted its stake in Allogene Therapeutics by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company's stock worth $5,944,000 after purchasing an additional 507,021 shares in the last quarter. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).